A recent testosterone product lawsuit alleges that the testosterone replacement therapy drug Axiron is unsafe and consumers who use Axiron are at an increased risk for blood clots and heart attacks.

A New Jersey resident has filed a testosterone drug lawsuit against Eli Lilly and Company for misrepresenting Axiron as a safe and effective treatment for adult males who have low or no testosterone (a condition called hypogonadism), claiming the drug causes serious medical problems, including life threatening cardiac events, strokes, and thromboembolic events.

Plaintiff Patrick Miller claims in the Axiron lawsuit that he was hospitalized in October 2012 after he suffered a heart attack resulting from taking Axiron to treat his “ low testosterone.”

Eli Lilly manufactures Axiron as a treatment option for low testosterone or “low-t.” The U.S. Food and Drug Administration (FDA) approved Axiron for the treatment of adult males who have hypogonadism (low or no testosterone) along with an associated medical condition such as failure of the testicles to produce testosterone, genetic problems, or chemotherapy.

The Axiron heart attack lawsuit alleges that the Eli Lilly failed to adequately warn physicians about the risks associated with Axiron and neglected to ensure consumers’ safety by recklessly marketing Axiron as a viable treatment for low testosterone and withholding facts about life-threatening health risks associated with the use of the drug.

What is Axiron?

Axiron is a testosterone replacement therapy used to treat men with very low levels of testosterone due to a serious medical condition. Axiron is only approved to treat low testosterone in conjunction with one of the following serious medical conditions:

• Hypogonadism
• Genetic problems with testosterone production
• Chemotherapy
• Problems such as with the hypothalmus or pituitary gland that control testosterone
• Missing or damaged testicles

Studies Link Axiron to Increased Risk of Heart Attacks

Numerous medical studies have uncovered a troubling link between Axiron and heart attacks. Some key study findings used in Axiron testosterone product lawsuits include a 2010 study by the New England Journal of Medicine, which was discontinued prematurely after an exceedingly high number of men in the testosterone group suffered adverse side effects.

Additionally, a study published in the 2013 Journal of the American Medical Association found that testosterone was linked to a 30 percent increased risk of heart attack and stroke in first 90 days of treatment while a January 2014 study published in PLoS One reported that testosterone replacement therapy doubles risk of heart attack for men over 65, and triples risk for men under 65 with pre-existing heart disease.

Miller is seeking all relief, general and special damages, and equitable relief for Eli Lilly’s alleged fraudulent misrepresentation of the side effects of Axiron and all reasonable court costs. He has demanded a jury trial for this case.

The Axiron Testosterone Product Lawsuit is Patrick Miller v. Lilly USA Inc. and Eli Lilly Company, Case No. 2:14-cv-06039, in the U.S. District Court for the District of New Jersey.